MMP9 and chronic myelogenous leukemia, BCR-ABL1 positive: Upon considering these scientific observations and our findings in the present study, we suggest that COL-3 may be considered as a treatment modality for CML patients in blast crisis, where it not only inhibits the production of MMP-9, but also induces cell death in the leukemic cells.